Clinical trial NCT04798339: Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA
Official title: A Phase 1b/2 Study Evaluating the Safety and Efficacy of Canakinumab With Darbepoetin Alfa in Patients With Lower-Risk Myelodysplastic Syndromes (MDS) Who Have Failed Erythropoietin Stimulating Agents (ESA)
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE1
PHASE2
Conditions: Myelodysplastic Syndromes
Keywords: MDS
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute
Sponsor class: OTHER
Collaborators: name: Novartis Pharmaceuticals
First posted: 2021-03-15
Enrollment: 13
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: This study is a multi-institution, open-label, Phase 1b/2 clinical trial evaluating the toxicity and efficacy of canakinumab in combination with darbepoetin alfa in patients with lower-risk MDS who have failed prior treatment with an Erythropoietin Stimulating Agent (ESA)

Detailed description: This study is a multi-institution, open-label, Phase 1b/2 clinical trial evaluating the toxicity and efficacy of canakinumab in combination with darbepoetin alfa in patients with lower-risk MDS who have failed prior treatment with an ESA. The study will be conducted in two parts, an initial Phase 1b dose escalation study followed by a dose expansion phase.

Eligibility criteria: Inclusion Criteria:

* Adequate organ function as defined by laboratory values per protocol
* Documented diagnosis of MDS by World Health Organization (WHO) criteria, further meeting the following criteria according to disease risk classification
* Patients must be transfusion dependent, defined as requirement for transfusion of at least 3 units of Packed Red Blood cells (PRBCs) 16 weeks for a Hgb\<9.0g/dL or, in non-transfusion dependent patients (\<3 units of PRBCs transfused in the preceding 16 weeks), must have a baseline Hgb of \<9.0 g/dL at time of study enrollment
* Eastern Cooperative Oncology Group (ECOG) Performance Status \</=2.
* Women of child bearing potential must have negative urine or serum pregnancy test within 28 days prior to start of study drug.
* Women of child bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence; tubal ligation, partner's vasectomy) prior to Cycle 1 Day 1 and for the duration of study participation.

Exclusion Criteria:

* Use of chemotherapeutic agents or experimental agents (agents that are not commercially available) for the treatment of MDS within 14 days of the first day of study drug treatment.
* Previous treatment with a hypomethylating agent (such as azacitidine, decitabine or investigational hypomethylating agent).
* Use of concurrent growth factors such as G-CSF, GM-CSF, or thrombopoietin mimetics during study except in cases of febrile neutropenia, where G-CSF can be used for short term. Growth factors must be stopped two weeks prior to study.
* Patient has any of the following cardiac abnormalities: (a) Uncontrolled, symptomatic congestive heart failure as designated by the treating physician (b) Myocardial infarction ≤ 6 months prior to enrollment (c) Unstable angina pectoris as designated by the treating physician (d) Serious uncontrolled cardiac arrhythmia as designated by the treating physician. (e) Uncontrolled hypertension as designated by the treating physician
* Known history of human immunodeficiency virus (HIV) (no laboratory testing is required), or active infection with Hepatitis B or Hepatitis C.
* Active tuberculosis (Tb) infection or documented, untreated latent Tb infection (all patients should undergo Tb risk evaluation prior to enrollment with Tb screening performed as per local guidelines,
* Active, uncontrolled infection at the time of enrollment, except in cases of localized infections that are unlikely to lead to a systemic infection such as onychomycoses or dental caries. Patients with new fever (\> 38.0 C) or respiratory symptoms are required to undergo laboratory screening for COVID-19
* Have undergone prior allo-HSCT for the treatment of MDS, or other hematologic disorder, or prior solid organ transplant.
* Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results.
* Prior malignancy active within the previous 2 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast.
* Patients with a condition requiring systemic treatment with corticosteroids within 14 days of study drug administration (i.e. prednisone at doses of \>10mg). Inhaled or topical steroids and adrenal/pituitary replacement doses \>10mg daily prednisone equivalents are permitted.
* Patients undergoing concurrent treatment with agents targeting tumor necrosis factor alpha (TNF) or IL-1 within 28 days of study enrollment.
* Patients who have received a live-virus vaccine within 30 days before study drug administration (patients should not be treated with live-virus vaccine while undergoing therapy).
* History of allergy or hypersensitivity to either darbepoetin alfa or the study drug or its components.
* Women of child bearing potential who are pregnant or breastfeeding.
* Subjects who are compulsorily detained for treatment of either a psychiatric or physical (e.g., infectious disease) illness.)

Primary outcomes:
measure: Phase 1b: Maximum Tolerated Dose (MTD)
timeFrame: up to 28 days per cohort
measure: Phase 2: Rate of Hematologic Improvement-Erythroid (HI-E) response
timeFrame: 8 - 12 weeks from baseline
Secondary outcomes:
measure: Phase 1b and Phase 2: Duration of Hematologic Improvement-Erythroid (HI-E) response
timeFrame: Up to 12 months per cohort
measure: Phase 1b and Phase 2: Degree in reduction of PRBC Transfusions
timeFrame: at 24 weeks per cohort
measure: Phase 2: Overall Response Rate (ORR)
timeFrame: Up to 60 months
measure: Phase 2: Duration of Response
timeFrame: Up to 60 months
measure: Phase 2: Overall Survival (OS)
timeFrame: Up to 60 months
measure: Phase 2: Progression Free Survival (PFS)
timeFrame: Up to 60 months
Other outcomes:
Locations:
city: Tampa
country: United States
facility: Moffitt Cancer Center
state: Florida
city: Atlanta
country: United States
facility: Emory-Winship Cancer Institute
state: Georgia
Study officials:
affiliation: Moffitt Cancer Center
name: David A Sallman, MD
role: PRINCIPAL_INVESTIGATOR
References: